Clinical Trials
28
Trial Phases
3 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
News
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
Nilo Therapeutics Emerges from Stealth with $101 Million to Develop Neural Circuit-Based Immunomodulation Therapies
Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases.
Merck Expands Tulisokibart Clinical Program with Three New Phase 2b Trials Across Immune-Mediated Inflammatory Diseases
Merck has initiated three Phase 2b trials evaluating tulisokibart, an anti-TL1A monoclonal antibody, in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis.
Eisai Presents 5-Year Survival Data for Lenvatinib Plus Pembrolizumab in Endometrial Cancer at ESMO 2025
Eisai will present 5-year overall survival data from the Phase 3 Study 309/KEYNOTE-775 trial evaluating lenvatinib plus pembrolizumab versus physician's choice in advanced endometrial carcinoma at ESMO 2025.
Cartography Biosciences Raises $67M Series B to Advance Novel T-Cell Engager for Colorectal Cancer
Cartography Biosciences secured $67 million in Series B funding led by Pfizer Ventures to advance its lead T-cell engager CBI-1214 targeting colorectal cancer into Phase 1 trials.
Biopharma M&A Activity Surges in Q3 2025 with $55.7 Billion in Acquisitions
The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.
Genmab Announces $5.2 Billion Acquisition of Merus to Expand Late-Stage Oncology Pipeline
Genmab will acquire Merus for $97.00 per share, representing a 41% premium and totaling approximately $5.2 billion in the largest deal in Genmab's history.
Pfizer Presents Breakthrough Cancer Data at ESMO 2025, Showcasing Unprecedented Survival Results
Pfizer will present data from more than 45 abstracts at ESMO 2025, including unprecedented survival results from the Phase 3 EV-303 trial evaluating PADCEV plus KEYTRUDA in muscle-invasive bladder cancer patients.
Merck and Siemens Expand Partnership to Accelerate AI-Driven Drug Discovery and Manufacturing
Merck and Siemens signed a new Memorandum of Understanding to deliver integrated digital workflows connecting drug discovery, development, and manufacturing through AI and automation technologies.
FDA Approves Injectable Keytruda, Marking New Era in Cancer Treatment Convenience
The U.S. Food and Drug Administration has approved an injectable subcutaneous form of Merck's blockbuster immunotherapy Keytruda, representing a significant advancement in cancer treatment administration.